AFMD Company Profile and Key Details

Q: Who are the executives of AFMD?

Dr. Wolfgang FischerMD, Chief Operating Officer & Member of Management BoardMr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsDr. Uwe ReuschHead of Cell CultureDr. Arndt Justus Georg Schottelius M.D., Ph.D.Chief Scientific Officer & Member of Management BoardDr. Adi HoessChief Executive Officer, MD & Member of Management BoardMs. Denise MuellerChief Bus. Officer & Member of Management BoardDr. Andreas Harstrick M.D.Chief Medical Officer & Member of Management BoardMary Beth SandinVice President of Marketing & CommunicationsProf. Melvyn LittleFounder & ConsultantMr. Michael WolfHead of Fin. & Admin.Dr. Arndt J. G. Schottelius M.D., Ph.D.Chief Scientific Officer & Member of Management BoardDr. Adi Hoess M.D., Ph.D.Chief Executive Officer, MD & Member of Management BoardMr. Angus W. SmithChief Financial Officer & Member of Management Board

NASDAQ : AFMD

Affimed NV

$0.18

At Close 4:00 PM

Not Actively Trading

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Affimed N.V. (AFMD) stock remained unchanged at $0.18 a share on NASDAQ. The stock opened at $0.18, fluctuating between $0.18 to $0.18 during the session.

Stock Snapshot

0.1815

Prev. Close

2.98M

Market Cap

0.1815

Day Low

-0.035658153241650295

P/E Ratio

-5.09

EPS (TTM)

-7.63

Cash Flow per Share

0.18

Open

16.39M

Number of Shares

0.1815

Day High

94.42%

Free Float in %

3.87

Book Value

22.06M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 10, 2025	0.04	0.05	0.04	0.04	66.93K
Jul 08, 2025	0.04	0.05	0.04	0.04	126.5K
Jun 25, 2025	0.10	0.10	0.08	0.08	46.84K
Jun 24, 2025	0.08	0.10	0.08	0.09	117.4K
Jun 23, 2025	0.08	0.10	0.07	0.09	107.09K
Jun 16, 2025	0.08	0.10	0.07	0.08	240K
Jun 09, 2025	0.07	0.10	0.06	0.07	96.38K
May 28, 2025	0.02	0.03	0.02	0.03	22.06M
May 27, 2025	0.02	0.03	0.02	0.02	310K
May 22, 2025	0.04	0.05	0.02	0.03	1.16M
May 21, 2025	0.08	0.09	0.03	0.05	1.31M
May 19, 2025	0.22	0.24	0.17	0.18	22.16M
May 16, 2025	0.18	0.57	0.18	0.28	913.06M
May 15, 2025	0.11	0.11	0.07	0.09	5.77M
May 14, 2025	0.11	0.15	0.10	0.13	7.93M
May 13, 2025	0.16	0.18	0.13	0.13	9.5M
May 12, 2025	0.70	0.73	0.69	0.69	97.14K
May 09, 2025	0.70	0.72	0.68	0.69	93.4K
May 08, 2025	0.69	0.70	0.68	0.70	93.08K
May 07, 2025	0.80	0.80	0.68	0.69	197.29K

Contact Details

Mannheim, 69120

Germany

https://www.affimed.com 496 221 674360

About Company

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Stock Peers

ARGX

3.05+0.36%

argenx SE$840.95 REGN

-2.07-0.27%

Regeneron Pharmaceuticals, Inc.$771.87 MDGL

-1.39-0.24%

Madrigal Pharmaceuticals, Inc.$582.34 UTHR

-8.94-1.80%

United Therapeutics Corporation$487.25 VRTX

-0.38-0.08%

Vertex Pharmaceuticals Incorporated$453.36 ALNY

0.4+0.10%

Alnylam Pharmaceuticals, Inc.$397.65 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-2.28-0.77%

Praxis Precision Medicines, Inc.$294.74 KRYS

-1.34-0.54%

Krystal Biotech, Inc.$246.54 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

The stock is currently mid-range between its 52-week high and low $0.02 and $8.95. With a market capitalization of about $2.98 million, Affimed N.V. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.07). Key stats such as the average daily volume over the past year has been around 15.65 million shares, in line with its 52-week average. Headquartered in Mannheim, None, Affimed N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shawn Leland, the company employs approximately 76 people and listed since September 12, 2014. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe.

Technical Performance

AFMD has shown mixed momentum, gaining 113.28% over the past week and -82.55% over the past quarter, though year-to-date performance is down -84.75%. Short-term trend indicators are bullishly aligned (SMA20 -73.2%, SMA50 -75.27%, SMA200 -91.58%). The stock’s 14-day RSI is 30.63 (weak momentum), while the ATR of 0.13 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.97% below its high and over 158.92% above its low.

Valuation Metrics

Affimed N.V. trades at a P/E ratio of -0.02, slightly below the S&P 500 average, with a price-to-sales ratio of 0.31 and a price-to-book ratio of 0.04 suggesting the stock is closer to book value. The P/FCF stands at -0.02, also above market averages.

Dividend & Fair Value

Affimed N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.97. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$1.38. The next quarter is forecast at -$0.86. Next year's EPS is expected at $16.10. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $0.10 to $0.10. The high target offers -44.44% upside. The low target suggests -44.44% downside. The mean target is $0.10. This offers -44.44% upside. Affimed N.V. earnings surprise history is a mixed track record. The quarter that ended June 11, 2025, missed forecasts by 165.38%. The prior quarter beat by 0.53%. Over the last six quarters, Apple has recorded several small beats. These include -20.23% in June 12, 2024.

Shareholding & Insider Activity

Affimed N.V. has 16.39 million shares outstanding. The public float is 15.48 million shares, elevated short interest at 3.75% of float. This equals 580.55 thousand shares. The short ratio is 4.6 days. Institutional investors hold 21.16% of the float. Insiders own 6.01%.

Financial & Profitability Overview

Over the trailing twelve months, Affimed NV generated $8.28M in revenue, or $0.55 per share. Gross margin was 100.00%, operating margin -1288.95%, and net profit margin -1280.22%. Returns are negative, with ROA at -109.04% and ROE at -183.26%.
On valuation metrics, Affimed NV trades at a P/E of -0.02, P/S of 0.31 and P/B of 0.04. The current ratio is 3.25 and quick ratio is 3.23. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 234.97 days. Debt-to-equity is 0.33, supported by a cash flow-to-debt ratio of -5.70.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Affimed NV posted revenue of $8.28M, down slightly from $41.35M in the prior quarter. Gross profit was $8.28M (margin 100.00%). Operating income was - $106.66M (margin -1289.0%). Net income was- $105.94M (EPS - $7.09).
The company ended the quarter with $72.90M in cash and short-term investments, a total debt of $19.35M, and net debt of - $19.18M. Total assets were $97.16M, with equity of $57.81M. Financials further reflected weakness, with operating cash flow of - $110.27M, free cash flow of - $114.00M, and capital expenditures of - $3.73M.

Price Forecast & Outlook

Our AI price prediction model suggests that Affimed N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by July 24, 2025, within a range of $0.00 to $0.00 3-Month Outlook: Projected rise of 104.55%, reaching $0.09 by September 23, 2025, with a range of $0.00 to $0.23. 1-Year Outlook: Projected loss of -77.27%, with price at $0.01 by June 25, 2026, within a range of $0.00 to $0.31.

Key Takeaways

Affimed N.V. (NASDAQ:AFMD) shares are down -84.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Affimed N.V. trading at a premium to the broader market with a P/E of -0.02. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $8.44, suggesting 19081.82% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term rise (104.55% over three months), and a longer-term loss (-77.27% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Affimed N.V. (AFMD) stock price?

Affimed N.V. (NASDAQ: AFMD) stock price is $0.18 in the last trading session. During the trading session, AFMD stock reached the peak price of $0.18 while $0.18 was the lowest point it dropped to. The percentage change in AFMD stock occurred in the recent session was 0% while the dollar amount for the price change in AFMD stock was $0.00.

AFMD's industry and sector of operation?

The NASDAQ listed AFMD is part of Biotechnology industry that operates in the broader Healthcare sector. Affimed N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AFMD?

Dr. Wolfgang Fischer
MD, Chief Operating Officer & Member of Management Board
Mr. Alexander Fudukidis
Head of Investor Relations & Director of Investor Relations
Dr. Uwe Reusch
Head of Cell Culture
Dr. Arndt Justus Georg Schottelius M.D., Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Adi Hoess
Chief Executive Officer, MD & Member of Management Board
Ms. Denise Mueller
Chief Bus. Officer & Member of Management Board
Dr. Andreas Harstrick M.D.
Chief Medical Officer & Member of Management Board
Mary Beth Sandin
Vice President of Marketing & Communications
Prof. Melvyn Little
Founder & Consultant
Mr. Michael Wolf
Head of Fin. & Admin.
Dr. Arndt J. G. Schottelius M.D., Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Adi Hoess M.D., Ph.D.
Chief Executive Officer, MD & Member of Management Board
Mr. Angus W. Smith
Chief Financial Officer & Member of Management Board

How AFMD did perform over past 52-week?

AFMD's closing price is 908.33% higher than its 52-week low of $0.02 where as its distance from 52-week high of $8.95 is -97.97%.

How many employees does AFMD have?

Number of AFMD employees currently stands at 76.

Link for AFMD official website?

Official Website of AFMD is: https://www.affimed.com

How do I contact AFMD?

AFMD could be contacted at phone 496 221 674360 and can also be accessed through its website. AFMD operates from Technologiepark, Mannheim, 69120, Germany.

How many shares of AFMD are traded daily?

AFMD stock volume for the day was 22.06M shares. The average number of AFMD shares traded daily for last 3 months was 15.65M.

What is the market cap of AFMD currently?

The market value of AFMD currently stands at $2.98M with its latest stock price at $0.18 and 16.39M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	76
Beta	2.07
Sales or Revenue	$8.28M
5Y Sales Change%	-0.859%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

AFMD Company Profile and Key Details

Affimed NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics